Baxter International (NYSE:BAX) Announces Earnings Results

Baxter International (NYSE:BAX) announced its earnings results on Thursday. The medical instruments supplier reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.19, FiscalAI reports. Baxter International had a positive return on equity of 16.15% and a negative net margin of 9.70%.The business had revenue of $2.96 billion for the quarter, compared to analysts’ expectations of $2.80 billion. During the same period last year, the firm posted $0.59 earnings per share. The business’s revenue for the quarter was up 5.3% on a year-over-year basis. Baxter International updated its FY 2026 guidance to 1.950-2.150 EPS.

Here are the key takeaways from Baxter International’s conference call:

• Second-quarter sales rose 5% organically to approximately $3 billion, with growth across all segments and geographies. Advanced Surgery and drug compounding were standout contributors, while hospital demand and order books remained solid.
• Baxter raised its 2026 organic sales-growth outlook to 2%-3% and adjusted EPS guidance to $1.95-$2.15 per share, helped by stronger year-to-date performance and a $75 million tariff refund.
• Adjusted EPS declined 5% to $0.56, reflecting higher-cost inventory, an unfavorable prior-year accounting comparison, and mix pressure from fast-growing but lower-margin drug compounding. Management expects operating margins to improve in the second half as these headwinds roll off and cost actions take effect.
• The Novum IQ LVP infusion pump remains subject to a shipment and installation hold while Baxter conducts verification testing and works with regulators. Injectable sales and parts of the pharmaceutical portfolio also remain constrained by supply issues, including problems at a contract manufacturer.
• Second-quarter free cash flow reached $181 million, bringing year-to-date free cash flow to $257 million. Management is increasingly confident it can reduce net leverage to approximately 3x by year-end, potentially creating capacity for tuck-in acquisitions or share repurchases.

Baxter International Stock Performance

NYSE BAX traded up $1.88 on Thursday, reaching $26.65. 22,670,769 shares of the stock were exchanged, compared to its average volume of 8,385,931. The company has a current ratio of 1.85, a quick ratio of 1.23 and a debt-to-equity ratio of 1.43. Baxter International has a one year low of $15.73 and a one year high of $30.00. The firm has a market capitalization of $13.76 billion, a PE ratio of -12.51, a PEG ratio of 3.93 and a beta of 0.62. The company’s 50-day simple moving average is $21.20 and its two-hundred day simple moving average is $19.56.

Baxter International News Summary

Here are the key news stories impacting Baxter International this week:

• Positive Sentiment: Baxter reported second-quarter adjusted earnings of $0.56 per share, exceeding the $0.36–$0.37 analyst consensus, while revenue rose 5.3% year over year to $2.96 billion, above expectations of approximately $2.80 billion. Baxter Reports Second-Quarter 2026 Results
• Positive Sentiment: The company raised its fiscal 2026 adjusted EPS guidance to $1.95–$2.15, from a prior range of $1.85–$2.05, and forecast revenue of $11.6–$11.7 billion, above the roughly $11.4 billion consensus. Robust demand for IV solutions and broad-based segment growth supported the improved outlook. Baxter raises annual profit forecast on strong demand for IV solutions
• Positive Sentiment: Management said results benefited from operating improvements and an additional tariff refund that was not included in its earlier guidance, reinforcing the view that Baxter’s turnaround is progressing. Baxter Jumps After Q2 Beat, Boosted 2026 Guidance
• Neutral Sentiment: Despite the earnings and revenue beats, adjusted earnings declined from $0.59 per share a year earlier, and margins contracted amid tariff and inflationary cost pressures. Investors will likely monitor whether the stronger outlook can be achieved without continued one-time benefits.
• Negative Sentiment: Baxter recently recalled certain antibiotic IV bags after cardboard material was reportedly found in the solution. The recall could create limited product-liability, operational, or reputational concerns, although it has not overshadowed the earnings-driven reaction. Baxter issues recall of antibiotic IV bags

Analyst Ratings Changes

BAX has been the subject of a number of research reports. Weiss Ratings raised shares of Baxter International from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th. The Goldman Sachs Group lifted their price target on shares of Baxter International from $19.00 to $21.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 15th. Zacks Research downgraded shares of Baxter International from a “hold” rating to a “strong sell” rating in a research report on Monday, July 13th. UBS Group upped their price objective on Baxter International from $19.00 to $25.00 and gave the stock a “hold” rating in a research note on Tuesday. Finally, Barclays raised their target price on Baxter International from $25.00 to $27.00 and gave the stock an “overweight” rating in a report on Friday, May 1st. Two analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and four have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Reduce” and a consensus target price of $21.09.

Institutional Trading of Baxter International

Hedge funds and other institutional investors have recently modified their holdings of the company. Imprint Wealth LLC purchased a new position in shares of Baxter International during the 3rd quarter valued at $27,000. MUFG Securities EMEA plc bought a new stake in Baxter International during the second quarter valued at about $46,000. Los Angeles Capital Management LLC bought a new stake in Baxter International during the fourth quarter valued at about $46,000. McMillan Office Inc. purchased a new position in shares of Baxter International in the fourth quarter valued at about $54,000. Finally, Parallel Advisors LLC lifted its position in shares of Baxter International by 113.3% in the third quarter. Parallel Advisors LLC now owns 3,971 shares of the medical instruments supplier’s stock valued at $90,000 after acquiring an additional 2,109 shares in the last quarter. 90.19% of the stock is owned by hedge funds and other institutional investors.

About Baxter International

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.